Curacle Co

Curacle Co P/B

The P/B (Price-to-Book Ratio) of Curacle Co (365270.KQ) as of Nov 4, 2026 is 7.97. In the previous year, P/B (Price-to-Book Ratio) was 9.87 — a change of -19.24% (lower).

P/B

7.97

YoY

-19.24%

Last updated:

P/B (Price-to-Book Ratio) of Curacle Co is 2025 7.97 . P/B (Price-to-Book Ratio) of Curacle Co was 2024 9.87 . It decreases by -19.24% lower compared to the previous year.

The Curacle Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
-175.78 KRW
Jan 1, 2019
-20.02 KRW
Jan 1, 2020
43.94 KRW
Jan 1, 2021
5.37 KRW
Jan 1, 2022
6.40 KRW
Jan 1, 2023
7.06 KRW
Jan 1, 2024
9.87 KRW
Jan 1, 2025
7.97 KRW
The Curacle Co P/B history
YEARP/BYoY
7.97-19.24%
9.87+39.76%
7.06+10.29%
6.40+19.16%
5.37-87.77%
43.94-319.50%
-20.02-88.61%
-175.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curacle Co Stock analysis

What does Curacle Co do? Curacle Co., Ltd. generates revenue through the research and development of synthetic drugs CU06-RE, CU01, and natural drug CU03, targeting intractable vascular diseases. These drugs address diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). The company leverages its SOLVADYS platform technology, a specialized platform for developing vascular endothelial dysfunction blockers, to advance its drug development pipeline. The primary buyers of Curacle's products are pharmaceutical companies and medical institutions seeking innovative treatments for vascular-related conditions. The company focuses on intractable vascular diseases, a niche segment where current treatments are limited, positioning its drugs as novel solutions. SOLVADYS platform technology is utilized by the company internally to enhance its research capabilities and streamline drug development processes. Curacle's business model centers on developing proprietary drug candidates and platform technology, with revenue streams derived from potential future licensing agreements, partnerships, or direct sales of its drug candidates. The company's focus on rare and complex vascular diseases ensures a targeted market segment with high unmet medical needs, attracting interest from specialized healthcare providers and pharmaceutical developers. Curacle Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curacle Co stock

P/B (Price-to-Book Ratio) of Curacle Co is 7.97 in 2025.

P/B (Price-to-Book Ratio) of Curacle Co changed from 9.87 to 7.97, representing a -19.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Curacle Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Curacle Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Curacle Co

All Key Metrics — Curacle Co